Back to results
US 2009/0270447 A1Published application
2-Aryl-and 2-Heteroarylthiazolyl Compounds, Methods for Their Preparation and Use Thereof
AssigneeWyeth
InventorsNan Zhang, Semiramis Ayral-Kaloustian, Thai Hiep Nguyen, Chuansheng Niu, Edward Christian Rosfjord, Ronald Suayan
Life of this patent
Estimating the term…
Abstract
The present invention discloses fused heterobicyclic 2-aryl- and 2-heteroarylthiazolyl compounds and their pharmaceutically acceptable salts and esters thereof, which are useful for inhibiting the growth of cancerous cells, inhibiting human breast carcinoma tumor growth in particular and to treat diseases or disorders associated with securin.
Claims23
A compounds of formula I:
- and pharmaceutically acceptable salts thereof,
- wherein
- A is H, C1-C3 alkyl, or acetyl;
- Z is NR3 or O;
- Q is —NR1R2, —NR3N(R3)2, —NR3OR3, or —OH;
- R1 and R2 are each independently H or C1-C3 alkyl, or R1 and R2 join together with the nitrogen atom to which each is attached, forming a 4 to 6 membered saturated heterocyclic ring comprising heteroatoms selected from 1-2 nitrogen atoms, 0-1 oxygen atom and 0-1 sulfur atom, said ring optionally substituted with one or more of R4;
- R3 at each occurrence is independently H or C1-C3 alkyl;
- R4 is C1-C3 alkyl, —N(R3)2, or —OH;
- Y1, Y2, Y3, and Y4 are the same or different, and are each independently N or CR5, or two R5 groups on adjacent carbon atoms join together, with the carbon atoms which they are bonded, to form a 9 to 10 membered bicyclic aryl ring or bicyclic heteroaryl ring, said ring comprising members selected from CR5 and N;
- R5 is independently H or is independently selected from C1-C3 alkyl, F, Cl, Br, I, CF3, NO2, —NR1R2, —CHO, —CONHAr, —C(R3)2OR3, —C(R3)2O[C(R3)2]Ar, —C(R3)2NR1R2, —C(R3)2NR3[C(R3)2]2NR1R2, —CO2R6, —SOR6, and —SO2R6, where Ar is phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-thienyl, 3-thienyl, 2-furyl, or 3-furyl, optionally substituted with one or more of R4;
- R6 is independently H or is independently selected from C1-C8 alkyl, C2-C8 alkenyl, and C2-C8 alkynyl, each optionally substituted with —NR1R2, —OR3, C4-C6 cycloalkyl, a saturated heterocyclic ring comprising heteroatoms selected from 0-1 nitrogen atom, 0-1 oxygen atom and 0-1 sulfur atom, or —COCH3, C4-C6 cycloalkyl, optionally substituted with R4;
- or a saturated heterocyclic ring comprising heteroatoms selected from 0-1 nitrogen atom, 0-1 oxygen atom and 0-1 sulfur atom, and optionally substituted with one or more of R4;
- and
- m is 0 or 1.
11 more elements
A compound selected from:
- and pharmaceutically acceptable salts thereof.
A compound selected from:
- 2-(4-dimethylamino-phenyl)-5-methyl-4,5,6,7-tetrahydro[1,3]thiazolo[4,5-c]pyridine-7-ol, (R,S)-2-(4-dimethylamino-phenyl)-4,5,6,7-tetrahydro[1,3]thiazolo[4,5-c]pyridin-7-ol, (R)-2-(4-dimethylamino-phenyl)-4,5,6,7-tetrahydro[1,3]thiazolo[4,5-c]pyridin-7-ol, (S)-2-(4-dimethylamino-phenyl)-4,5,6,7-tetrahydro[1,3]thiazolo[4,5-c]pyridin-7-ol, (7R,S)-2-(4-pyrrolidin-1-yl-phenyl)-4,5,6,7-tetrahydro[1,3]thiazolo[4,5-c]pyridin-7-ol, (7R)-2-(4-pyrrolidin-1-yl-phenyl)-4,5,6,7-tetrahydro[1,3]thiazolo[4,5-c]pyridin-7-ol, (7S)-2-(4-pyrrolidin-1-yl-phenyl)-4,5,6,7-tetrahydro[1,3]thiazolo[4,5-c]pyridin-7-ol, 2-(2-hydroxymethyl-4-dimethylamino-phenyl)-4,5,6,7-tetrahydro[1,3]thiazolo[4,5-c]pyridine-7-ol, methyl 5-(dimethylamino)-2-(7-hydroxy-4,5,6,7-tetrahydro[1,3]thiazolo[4,5-c]pyridine-2-yl)benzoate, (7R,7S)-2-(2-hydroxymethyl-4-pyrrolidin-1-yl-phenyl)-4,5,6,7-tetrahydro[1,3]thiazolo[4,5-c]pyridin-7-ol, (7R)-2-(2-hydroxymethyl-4-pyrrolidin-1-yl-phenyl)-4,5,6,7-tetrahydro[1,3]thiazolo[4,5-c]pyridin-7-ol, (7R,7S)-2-(2-hydroxymethyl-4-pyrrolidin-1-yl-phenyl)-4,5,6,7-tetrahydro[1,3]thiazolo[4,5-c]pyridin-7-ol, methyl 5-(4-pyrrolidin-1-yl)-2-(7-hydroxy-4,5,6,7-tetrahydro[1,3]thiazolo[4,5-c]pyridin-2-yl)benzoate, 2-(2-amino-4-pyrrolidin-1-yl-phenyl)-4,5,6,7-tetrahydro[1,3]thiazolo[4,5-c]pyridin-7-ol, 2-(2-nitro-4-pyrrolidin-1-yl-phenyl)-4,5,6,7-tetrahydro[1,3]thiazolo[4,5-c]pyridin-7-ol, 2-[3-bromo-4-(dimethylamino)phenyl]-6,7-dihydro-4H-pyrano[3,4-d][1,3]thiazol-7-ol, 2-[4-(dimethylamino)phenyl]-6,7-dihydro-4H-pyrano[3,4-d][1,3]thiazol-7-ol and pharmaceutically acceptable salts thereof.
The method of claim 18 or 19, wherein tumor growth is associated with a cancer selected from:
- breast, colon, lung, prostate, melanoma, epidermal, leukemia, kidney, bladder, mouth, larynx, esophagus, stomach, ovary, pancreas, liver, skin, thyroid, prostate and brain cancer.
Dependencies are inferred from the claim text.